Skip to content
L152L152L152

Drawing based on the label description. No photo yet.

“They are available as follows: NDC 46708-113-30 bottles of 30 tablets NDC 46708-113-31 bottles of 100 tablets NDC 46708-113-91 bottles of 1000 tablets NDC 46708-113-10 carton of 100 (10 x 10) tablets unit-dose The 100 mg tablets are blue, film coated, round, biconvex tablets debossed with 'L152' on one side and breakline on other side”

L152 pill

Pill with imprint L152 is blue, round, 10 mm and has been identified as Metoprolol Tartrate 100 mg. It is used for high blood pressure, heart failure and chest pain (angina). It is supplied by Alembic Pharmaceuticals Limited.

Metoprolol Tartrate 100 mg

Imprint
L152
Strength
100 mg
Used for
High blood pressure, heart failure and chest pain (angina)
Color
Blue
Shape
Round
Size
10 mm
Score
Breaks into 2 pieces
Form
Tablet
Manufacturer
Alembic Pharmaceuticals Limited
Drug class
Beta blocker (heart and blood pressure medicine)
NDC
46708-114, 46708-114-30, 46708-114-31, 46708-114-91, 46708-114-10

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Metoprolol Tartrate pills and guides

What is Metoprolol Tartrate used for?

Metoprolol Tartrate is used for high blood pressure, heart failure, chest pain (angina) and atrial fibrillation (irregular heartbeat).

Medicine type
Beta blocker (heart and blood pressure medicine)
Official uses from the US prescribing label

Hypertension

Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Metoprolol tartrate tablets may be administered with other antihypertensive agents.

Angina Pectoris

Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.

Myocardial Infarction

Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.

From the FDA-approved label on DailyMed (published Sep 29, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows L152 and the other side has only a score line.
  • It is blue, round, 10 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Metoprolol Tartrate

Inactive: Cellulose, Microcrystalline, Lactose Monohydrate, Povidone, Croscarmellose Sodium, Colloidal Silicon Dioxide, Magnesium Stearate, Hypromelloses, Titanium Dioxide, Polyethylene Glycol 3350, Fd&c Blue No. 2, Fd&c Blue No. 1

Other pills with imprint L 152

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Metoprolol Tartrate pills